concentrato per soluzione per infusione

DRUG4 trials

Sponsors

Bristol-Myers Squibb International Corporation, Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l., Daehwa Pharmaceutical Co. Ltd., Fondazione Ricerca Traslazionale

Conditions

Early Stage Non-Small Cell Lung Cancer (NSCLC)Extensive-Stage Small-Cell Lung Cancer (ES SCLC)Recurrent or Metastatic HER2 Negative Breast Cancerstage III PD-L1 positive Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Phase 2 trial of Translational approach to first line cHemoimmunotherapy followed by maintenance with pembrOlizumab and olaparib in Extensive-Stage Small-Cell Lung CanceR (THOR trial)

RecruitingCTIS2024-514666-39-00

Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.Extensive-Stage Small-Cell Lung Cancer (ES SCLC)

Start: 2023-03-16Target: 60Updated: 2025-06-11

A Multinational, Multicenter, Open-label, Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of Oral Paclitaxel (DHP107) Compared to IV Paclitaxel as First-line Therapy in Patients with Recurrent or Metastatic HER2 Negative Breast Cancer

Active, not recruitingCTIS2024-517090-24-00

Daehwa Pharmaceutical Co. Ltd.Recurrent or Metastatic HER2 Negative Breast Cancer

Start: 2020-10-09Target: 10Updated: 2026-01-13

Neoadjuvant chemo-immunotherapy for stage III PD-L1 positive Non-Small Cell Lung Cancer (NSCLC)

RecruitingCTIS2024-519205-35-01

Fondazione Ricerca Traslazionalestage III PD-L1 positive Non-Small Cell Lung Cancer (NSCLC)

Start: 2025-07-08Target: 30Updated: 2025-09-10

Phase 3

Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC

CompletedCTIS2022-501360-18-00

Bristol-Myers Squibb International CorporationEarly Stage Non-Small Cell Lung Cancer (NSCLC)

Start: 2017-03-15End: 2024-12-03Target: 194Updated: 2024-12-03